Geburtshilfe Und Frauenheilkunde最新文献

{"title":"Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.","authors":"Dominik Denschlag, Bastian Czogalla, Florian Heitz, Markus Kerkmann, Laura-Christin Fangmann, Philip H Klecker, Frederik A Stuebs, Linn Wölber, Julia Radosa, Pia C Lodde, Stephan Seitz, Christian George, Pawel Mach, Angelina Fink, Davit Bokhua, Nikolaus deGregorio, Björn Lampe, Franziska Hemptenmacher, Verena Friebe, Markus Fleisch, Pauline Wimberger, Anna Jaeger, Andreas Schnelzer, Suzana Mittelstadt, Dominik Ratiu, Michael Eichbaum, Adriana Haus, Matthias Kalder, Beyhan Ataseven, Willibald Schröder, Holger Bronger, Jens Kosse, Uwe Andreas Ulrich, Gabriele Elser, Philipp Harter","doi":"10.1055/a-2520-5736","DOIUrl":"10.1055/a-2520-5736","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world data on treatment patterns and outcomes in recurrent or metastatic cervical cancer (r/mCC) are lacking.</p><p><strong>Methods: </strong>This first national quality assurance initiative was a retrospective analysis of patients with r/mCC diagnosed between 2018 and 2022, who were identified from medical records of 31 gynecologic cancer centers in Germany. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively. Progression-free (PFS) and overall survival (OS) were calculated using Kaplan-Meier analysis.</p><p><strong>Results: </strong>A total of 503 eligible patients (median age 55 years) were analyzed for r/mCC. 276/503 patients (55%) received first-line (1L) chemotherapy (platinum combination: 247/276; 79%) followed by targeted antibody therapy with bevacizumab (177/247; 72%), immunotherapy (19/247; 8%), or both combined (50/247; 20%). 111/503 (22%) received chemotherapy only (platinum combination: 64/111; 58%, platinum mono: 35/111; 31%, or platinum-free: 12/111; 11%), and 110/503 (22%) did not receive any systemic treatment (the remaining 6/503 patients received immunotherapy only). For these subgroups after a median follow-up of 16 months, the PFS was 12 months (95% CI 11-14), 8.8 months (95% CI 7.1-11), and 3 months (95% CI 2.3-4.8), and OS was 25 months (95% CI 21-31), 17 months (95% CI 14-22), and 3.6 months (95% CI 2.8-5.3), respectively. 176/283 (62%) patients who developed progressive disease (PD) were treated with second-line (2L) therapy.</p><p><strong>Conclusion: </strong>Only half of the patients with r/mCC were treated 1L with platinum-combination therapy including antibody therapy according to national guidelines. Moreover, 22% at initial diagnosis and 38% of patients at PD were not treated with systemic therapy at all. This might reflect poor general performance status, patients' preference, and/or lack of effective therapies especially in 2L treatment.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"520-532"},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.","authors":"Diana Lüftner, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A Fasching, Christian Jackisch, Frederik Marme, Katharina Keller, Manuel Hörner, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Julia C Radosa, Maggie Banys-Paluchowski, Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin-Andrei Taran, Wolfgang Janni, Rachel Würstlein, Michael P Lux","doi":"10.1055/a-2515-2366","DOIUrl":"10.1055/a-2515-2366","url":null,"abstract":"<p><p>The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"507-519"},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Analysis of the Incidence of Serous Tubal Intraepithelial Carcinoma (STIC) in Germany - Evaluation of the Cancer Registry of the Federal State of Rhineland-Palatinate from 2016 to 2023.","authors":"Valerie Catherine Linz, Alina Breuer, Philipp Leppert, Nils Herm-Stapelberg, Katja Schwarzer, Annette Hasenburg","doi":"10.1055/a-2555-4602","DOIUrl":"10.1055/a-2555-4602","url":null,"abstract":"<p><strong>Introduction: </strong>Serous tubal intraepithelial carcinomas (STIC) are classified as precursor lesions of high-grade serous carcinomas (HGSC) in women. STIC are rare and their incidence, prognosis and therapy remain unclear. Since 2021, all cases of isolated STIC in Germany must be reported, which means that all STICs in the German federal state of the Rhineland-Palatine (RLP) are available for evaluation.</p><p><strong>Material and methods: </strong>A systematic search of the pathology reports in the RLP cancer registry was carried out for the period 01/2016-12/2023 using keywords related to STIC, and the results of the search were evaluated.</p><p><strong>Results: </strong>382 pathology reports were identified as relevant and screened. A total of seven patients with isolated STIC were reported to the RLP registry in the years 2020-2022. This corresponds to 0.014% of all reported cases of cancer in women in RLP in this period. Six patients had a diagnosis of isolated STIC, identified during risk-reducing salpingo-oophorectomy (RRSO). The mean patient age at the time of RRSO was 60.29 (± 7.09) years. RRSO was carried out on average 9.38 (± 6.75) years after a primary diagnosis of breast cancer/DCIS in five patients. No HGSC was reported for any of the patients with isolated STIC in the follow-up period until 01/2024. 43 synchronous STICs were reported for the period from 01/2016 to 12/2023.</p><p><strong>Conclusion: </strong>2-3 diagnoses of isolated STIC were recorded annually in RLP in the years 2020-2022. To date, there have been no reports of HGSC in these patients. In the future, the systematic recording of STICs will be expanded to include the cancer registries of other federal states of Germany and it will be possible to obtain valid data on the incidence of STIC in Germany. The collected data will also provide the basic information for a national STIC registry.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"541-547"},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor on \"Effects of Systematically Guided vs. Self-Directed Laparoscopic Box Training on Learning Performances\".","authors":"Florian Recker, Ricarda Neubauer","doi":"10.1055/a-2539-5940","DOIUrl":"10.1055/a-2539-5940","url":null,"abstract":"","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"548-550"},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.","authors":"Wolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A Fasching, Christian Jackisch, Frederik Marme, Manuel Hörner, Katharina Keller, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Maggie Banys-Paluchowski, Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin-Andrei Taran, Diana Lüftner, Rachel Würstlein, Julia C Radosa","doi":"10.1055/a-2533-2783","DOIUrl":"10.1055/a-2533-2783","url":null,"abstract":"<p><p>This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"493-506"},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024).","authors":"Markus Wallwiener, Marco Johannes Battista, Eike-Christian Burandt, Wolfgang Cremer, Gerlinde Egerer, Mathias K Fehr, Markus Follmann, Paul Gass, Heidemarie Haase, Philipp Harter, Florian Heitz, Simone Hettmer, Lars-Christian Horn, Ingolf Juhasz-Böss, Karin Kast, Günther Köhler, Thomas Kröncke, Katja Lindel, Alexander Mustea, Jan Philipp Novotny, Edgar Petru, Peter Reichardt, Kerstin Rhiem, Hans-Georg Strauß, Clemens Tempfer, Falk C Thiel, Uwe Andreas Ulrich, Thomas Vogl, Dirk Vordermark, Dominik Denschlag","doi":"10.1055/a-2496-2591","DOIUrl":"10.1055/a-2496-2591","url":null,"abstract":"<p><p><b>Purpose</b> This is an official, recently updated guideline published and coordinated by the German Society of Gynecology and Obstetrics ( <i>Deutsche Gesellschaft für Gynäkologie und Geburtshilfe</i> , DGGG) together with the Austrian Society of Gynecology and Obstetrics ( <i>Österreichische Gesellschaft für Gynäkologie und Geburtshilfe</i> , OEGGG) and the Swiss Society of Gynecology and Obstetrics ( <i>Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe</i> , SGGG) as part of the guidelines program. Because of their rarity and heterogeneous histopathology, uterine sarcomas are challenging in terms of their clinical management, and treatment requires a multidisciplinary approach. <b>Methods</b> This S2k guideline was first published in 2015. The update published here is again the result of a structured consensus of a representative interdisciplinary group of mandate holders and experts who carried out a selective search of the literature on uterine sarcomas. Members of the participating professional societies achieved a formal consensus on recommendations and statements after a structured consensus process. <b>Recommendations</b> Recommendations were made about the epidemiology, classification, staging of uterine sarcomas, symptoms, general diagnostic workup, general pathology and genetic predisposition for uterine sarcomas, leiomyosarcomas, endometrial stromal sarcomas (low-grade and high-grade), undifferentiated uterine sarcomas, adenosarcomas, and rhabdomyosarcoma of the uterus in children and adolescents. The guideline also discusses the follow-up of uterine sarcomas, the management of morcellated uterine sarcomas, and the information provided to patients.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 4","pages":"378-394"},"PeriodicalIF":2.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sentinel Lymphonodectomy in Early Vulvar Cancer in Daily Practice: a Multicenter Experience from Germany.","authors":"Philipp Soergel, Matthias Hempel, Julia Gallwas, Christian Dannecker, Linn Woelber, Ruediger Klapdor, Peer Hantschmann, Dirk M Forner, Paul Gass, Monika Hampl","doi":"10.1055/a-2541-2191","DOIUrl":"10.1055/a-2541-2191","url":null,"abstract":"<p><strong>Objective: </strong>Inguinal sentinel lymph node dissection has been shown to be safe in early vulvar cancer in several studies and is considered or even recommended in many guidelines. The prognosis of inguinal recurrence is often poor and associated with significant mortality. To ensure an acceptably low false-negative rate and recurrence, vulvar sentinel lymph node dissection should only be performed using high-quality standards. This retrospective study aims to investigate the incidence of isolated groin recurrence in daily practice in six large cancer centers in Germany.</p><p><strong>Methods: </strong>We identified all patients with early vulvar cancer in 2009-2015 who underwent inguinal sentinel lymphonodectomy and presented with node-negative final histologic results. Patient details regarding disease stage, sentinel procedure, and follow-up were examined using local cancer databases and patient registries.</p><p><strong>Results: </strong>A total of 414 patients with available follow-up data were found, with a mean follow-up time of 38.4 months. The mean tumor size, measured in the dermal plane before surgery, was 40.0 mm, with a median tumor size of 36 mm. Isolated groin recurrence was found in 13 of 414 cases, leading to an isolated groin recurrence rate of 3.1%. The mean time to isolated groin recurrence was 17.7 months. There was no statistically significant association of any of the different quality requirements (tumor size < 4 cm, unifocal tumor, histologic ultra-staging, and preoperative exclusion of suspicious groins) with isolated groin recurrence.</p><p><strong>Conclusion: </strong>Sentinel lymphadenectomy in vulvar cancer is a safe procedure in daily practice. The requirements of the cancer guidelines (unifocal tumor, ≤ 4 cm, histologic ultrastaging, and exclusion of suspicious groins preoperatively) should be followed to ensure a low isolated groin recurrence rate. However, in this study, we could not find any difference between the patients who fulfilled the guideline requirements and those who did not.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"533-540"},"PeriodicalIF":2.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Results for the Evaluation of the Cervical Cancer Screening Carried Out in 2021 and 2022 in the Context of the Organized Cancer Screening Program (oKFE): Part 1 - Primary Screening.","authors":"Juliane Hellfritsch, Marieluise Panzer, Sebastian Wagner, Kathleen Nieschke, Martin Grohmann","doi":"10.1055/a-2502-6915","DOIUrl":"10.1055/a-2502-6915","url":null,"abstract":"<p><p>Organized cancer screening programs (oKFE) aim to detect and treat various cancers in their early stages. The German oKFE Directive has set out the requirements for evaluating the efficacy, quality, and safety of such programs. The first evaluation report on the cervical cancer screening program in Germany was published in May 2024 and covers the years 2021 and 2022. Women with statutory health insurance who are above the age of 20 and live in Germany are entitled to be screened for cervical cancer. Between the ages of 20 and 34 years, women are offered an annual cytology-based examination. From the age of 35 years and above, screening consists of a cytology examination and an HPV test (co-testing). The current evaluable data consists of pseudonymized data obtained from statutory health insurance companies and service providers as defined by the specifications of the IQTIG. The evaluation shows that around three million women between 20 and 34 years of age undergo cervical cancer screening every year, which corresponds to a response rate of 45%. As regards the co-testing carried out in women aged 35 years and above, around 2.3 million women with statutory health insurance had cytological examinations and co-testing in 2021 and 1.3 million women were similarly examined in 2022. The participation rate for this cohort cannot yet be determined as the three-year interval for persons eligible for this type of screening cannot be depicted using only two years of data. 97% of cytology smears were unremarkable. Fewer than 0.1% of smears resulted in cytological findings indicating precancerous cervical lesions or cervical malignancies. The average positive rate for HPV tests carried out as part of co-testing was 8.56%. The high-risk human papilloma viruses 16/18 were identified in 30% of cases with positive HPV tests, and the presence of these high-risk viruses increased in parallel with an increase in the severity of cytological findings. More than 30% of insured women aged between 20 and 34 years have been fully vaccinated against HPV. The limitations of this evaluation are the short observation period, some data gaps, and the not yet implemented combination of screening data with data from the cancer registries of the German federal states. It is not yet possible to make valid statements about the acceptance of the screening program and the long-term impact of this program.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 4","pages":"417-433"},"PeriodicalIF":2.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy, Childbirth and Puerperium in Women with Spinal Cord Injury: Guideline of the DGGG and DMGP (S2k-Level, AWMF Registry No. 179/002, August 2024.","authors":"Markus Schmidt, Anke Jaekel, Sue Bertschy, Ute Lange, Simone Kues, Kai Fiebag, Gesa Cohrs, Ulrich Mehnert, Doris Knorr, Marlies Onken, Amke Baum, Barbara Schilcher, Ines Kurze","doi":"10.1055/a-2490-2876","DOIUrl":"10.1055/a-2490-2876","url":null,"abstract":"<p><p>This guideline on pregnancy, childbirth and puerperium for women with spinal cord injury (SCI) presents general issues relating to the wish to have children and pregnancy in the context of SCI. The guideline was developed by the German-speaking Medical Society for Paraplegia ( <i>Deutschsprachige Medizinische Gesellschaft für Paraplegiologie</i> , DMGP) and the German Society for Gynecology and Obstetrics ( <i>Deutsche Gesellschaft für Gynäkologie und Geburtshilfe</i> , DGGG). As there were no generally available evidence-based guidelines about this complex set of problems, this new guideline aims to standardize procedures using a structured consensus-of-experts approach. The aim is to establish general interdisciplinary standards and provide practical assistance for the care and counseling of women with SCI who wish to have children/are pregnant and thereby close the identified gaps in medical care, information, interdisciplinary cooperation and research.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 3","pages":"265-281"},"PeriodicalIF":2.4,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Technology-Supported Ultrasound Training in Prenatal Diagnosis through an Adaptive Image Recognition Training System (AdaptUS).","authors":"Talia Sachs, Stefan Michel, Katarina Koziol, Alex Kunz, Agnes Wittek, Ricarda Neubauer, Hannah Klinkhammer, Johannes Weimer, Brigitte Strizek, Florian Recker","doi":"10.1055/a-2510-7185","DOIUrl":"10.1055/a-2510-7185","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Prenatal diagnostics, particularly ultrasound examinations, are vital for monitoring fetal development and detecting potential complications. Traditional ultrasound training often lacks adequate focus on image recognition and interpretation, which are crucial for accurate diagnostics. This study evaluates the effectiveness of the AdaptUS module, a technology-supported, adaptive learning platform designed to enhance ultrasound diagnostic skills in prenatal medicine.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A prospective cross-sectional study was conducted with 76 medical students from the German University Hospital, divided into an intervention group (n = 37) and a control group (n = 39). The intervention group engaged with the AdaptUS module, which adjusts its content based on individual performance. More precisely, it is a learning program for ultrasound images that, while not directly adaptive to the user's skill level, can be considered adaptive in the sense that incorrectly answered images are presented again for re-interpretation. However, the images are currently shown at random and are not yet adjusted to the user's abilities, ensuring that the challenge is consistent but not tailored to skill level. It is important to note that this is not an ultrasound image software, but rather an image interpretation software designed to help users improve their diagnostic skills through repeated exposure to medical images. In contrast, the control group did not receive this training. Both groups were assessed on their ultrasound diagnostic skills at the beginning and end of the semester using a series of 16 questions, which involved interpreting images correctly rather than a standard multiple-choice format. Statistical analysis was performed to compare the pre- and post-test results within and between the groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The intervention group showed a significant improvement in their mean test scores, increasing from 70.9% to 86.0% (p &lt; 0.001), while the control group's scores decreased slightly from 62.0% to 59.0%, though this change was not statistically significant. The difference in score improvements between the intervention and control groups was statistically significant (p &lt; 0.001). The feedback from students in the intervention group was overwhelmingly positive, highlighting the system's flexibility in addressing individual learning needs and suggesting its potential for broader integration into medical curricula.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;The AdaptUS training module significantly enhances ultrasound diagnostic skills, particularly in prenatal medicine, by providing a personalized learning experience that addresses the gaps in traditional training methods. The success of AdaptUS underscores the importance of integrating adaptive learning technologies into medical education to bridge the gap between theoretical knowledge and practical application. Future research should explore the long","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 3","pages":"323-332"},"PeriodicalIF":2.4,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}